oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 213 )

2018 ( 437 )

2017 ( 458 )

2016 ( 555 )

Custom range...

Search Results: 1 - 10 of 188150 matches for " B. Garrido-Suárez "
All listed articles are free for downloading (OA Articles)
Page 1 /188150
Display every page Item
Introducción de la suplementación con formulaciones Vimang en el síndrome doloroso regional complejo: experiencia en 15 pacientes Introduction of supplementation with Vimang formulations in complex regional pain syndrome: Experience in 15 patients
B. Garrido-Suárez,M.C. Rabí,F. Bosch,G. Garrido-Garrido
Revista de la Sociedad Espa?ola del Dolor , 2009,
Abstract: Introducción: En la actualidad el estrés oxidativo, la neuroinflamación y la activación glial han adquirido relevancia en la fisiopatología del síndrome doloroso regional complejo (SDRC), de ahí que la terapia con agentes antioxidantes e inhibidores de la producción de citocinas proinflamatorias ha comenzado a ensayarse. El Vimang es una marca comercial registrada que cubre varios tipos de formulaciones a partir del extracto de la corteza del árbol de mango con efecto inhibidor de la activación del factor de transcripción nuclear kB (NFkB), promotor de la expresión de mediadores y sistemas enzimáticos involucrados en la inflamación y el dolor, el estrés oxidativo y la plasticidad sináptica. Objetivo: El propósito del presente estudio fue determinar la actividad analgésica de la suplementación con formulaciones Vimang en 15 pacientes con SDRC y la posible mejoría de la capacidad funcional postratamiento. Material y métodos: Los pacientes recibieron Vimang tabletas 1.800 mg/día/8 h, crema 1,2% en el miembro afectado 3 veces/día y un bloqueo simpático semanal durante 4 meses. Se introdujo la fisioterapia al mes. Las variables evaluadas fueron las puntuaciones diarias medias de dolor (PDMD) mediante una escala de Likert, el área e intensidad de la alodinia mecánica dinámica, la alodinia al frío, somática profunda y la frecuencia del dolor paroxístico. Se aplicó la escala de Enneking et al. modificada para evaluar la funcionabilidad articular. Resultados: Las PDMD y el resto de las alteraciones sensoriales se redujeron significativamente desde la semana 2 a 3 de iniciado el tratamiento respecto a los valores iniciales. La funcionabilidad del miembro afectado aumentó de un promedio de 22,7 a 78,7%. Estas formulaciones pudieran introducirse en el tratamiento del SDRC, pero es necesario sistematizar los estudios. Introduction: Currently, oxidative stress, neuroinflammation and glial activation are accepted as playing a pathophysiological role in complex regional pain syndrome (CRPS) and consequently antioxidant agents and proinfl ammatory cytokine inhibitors have begun to be assessed in the treatment of this disorder. Vimang is a new phytodrug prepared from the stem bark of Mangifera indica L., registered in Cuba with inhibitory effect on nuclear transcription factor kB (NFkB), which induces expression of some mediators and enzymes involved in inflammation, oxidative stress, pain, and synaptic plasticity. Objective: To determine the analgesic effects of Vimang tablets and 1.2% cream as a topical agent in 15 patients with CRPS, as well as possible improvemen
Utilidad del Extracto de Mangifera Indica L (VIMANG) en el Síndrome Doloroso Regional Complejo: A propósito de un caso Usefulness of Mangifera Indica L (Vimang ) in the treatment of Complex Regional Pain Syndrome (CRPS): A case report
B. Garrido-Suárez,F. Bosch,G. Garrido-Garrido,R. Delgado-Hernández
Revista de la Sociedad Espa?ola del Dolor , 2007,
Abstract: Los avances en el conocimiento actual de la fisiopatología del Síndrome Doloroso Regional Complejo (SDRC), conducen a la búsqueda de nuevos fármacos dirigidos a los blancos moleculares que se involucran en sus complejos mecanismos. En la actualidad se considera el papel activo de la neuroinflamación en el fenómeno de hiperexcitabilidad del cuerno dorsal espinal y el establecimiento de la sensibilización central dentro de sus procesos subyacentes. El Extracto obtenido de la corteza de variedades seleccionadas de la especie Mangifera indica L. y que se comercializa en Cuba bajo la Marca Registrada VIMANG , posee actividad antioxidante, antiinflamatoria y antihiperalgésica in vivo. Por otra parte estudios in vitro demostraron su efecto inhibidor sobre múltiples moléculas que participan en la cascada de la sensibilización central y en un modelo de isquemia-reperfusión sus cualidades neuroprotectoras. Presentamos el caso de una paciente con diagnóstico de SDRC tipo II, secundario a una lesión del plexo braquial, con sección del nervio radial a nivel humeral que fue provocada por el desplazamiento de la fractura del húmero izquierdo. La paciente llega a nuestro servicio a los 4 meses de evolución, con síntomas sensoriales, dolor persistente quemante y paroxístico, alodinia mecánica, edema, cambios vasomotores hacia la hiperhemia y mano en flexión por pérdida de la función motora de los músculos extensores del antebrazo. Con compromiso de la articulación del carpo y hombro de limitación severa y dolor de valor 5 en una escala numérica de Likert. El estudio de conducción nerviosa mostró alteraciones mielínico-axonales discretas del nervio mediano y mielínico-axonales severas del nervio radial. Se instauró el tratamiento con Vimang (300mg) 2 tabletas cada 8 horas por 4 meses y la aplicación local de la crema Vimang 3 veces al día, asociado a los bloqueos simpáticos y somáticos para miembro superior y a la fisioterapia. La evolución clínica y electrofisiológica fue muy favorable. Este caso constituye el primero descrito en la literatura, en el cual se introduce este producto a la terapia múltiple del síndrome, se deben dirigir los estudios básicos y clínicos en este sentido, dadas las posibilidades terapéuticas del Vimang en el SDRC. Advances in our understanding of Complex Regional Pain Syndrome (CRPS) physiopathology have led to new drugs targeted toward molecular mediators involved in the complex mechanisms of pain. Neuroinflammation is thought to have an active role in phenomena underlying spinal cord dorsal horn hyperexcitability and the establishment of cen
Introducción de la suplementación con formulaciones Vimang? en el síndrome doloroso regional complejo: experiencia en 15 pacientes
Garrido-Suárez,B.; Rabí,M.C.; Bosch,F.; Garrido-Garrido,G.; Delgado-Hernández,R.;
Revista de la Sociedad Espa?ola del Dolor , 2009,
Abstract: introduction: currently, oxidative stress, neuroinflammation and glial activation are accepted as playing a pathophysiological role in complex regional pain syndrome (crps) and consequently antioxidant agents and proinfl ammatory cytokine inhibitors have begun to be assessed in the treatment of this disorder. vimang? is a new phytodrug prepared from the stem bark of mangifera indica l., registered in cuba with inhibitory effect on nuclear transcription factor kb (nfkb), which induces expression of some mediators and enzymes involved in inflammation, oxidative stress, pain, and synaptic plasticity. objective: to determine the analgesic effects of vimang? tablets and 1.2% cream as a topical agent in 15 patients with crps, as well as possible improvement in post-treatment functional capacity. material and methods: the patients received a daily dose of 1800 mg of vimang? tablets for 120 days, 1.2% cream in the affected limb 3 times/day, and sympathetic blocks once a week for 4 months. physiotherapy was introduced after 30 days. the variables evaluated were changes in average daily pain score through a likert scale, the area and rate of dynamic mechanical allodynia, rate of cold allodynia, deep somatic allodynia and frequency of burning spontaneous pain. a modified scale of enneking et al. was applied to evaluate functional capacity. results: the average daily pain score and sensory abnormalities significantly improved from week 2-3. on average, the functional capacity of the affected limb increased from 22.7 % to 78.7%. our results suggest that vimang? formulations might be useful in crps treatment. however, further studies are required.
A Mangifera indica L. Extract Could Be Used to Treat Neuropathic Pain and Implication of Mangiferin
Bárbara B. Garrido-Suárez,Gabino Garrido,Rene Delgado,Fe Bosch,María del C. Rabí
Molecules , 2010, DOI: 10.3390/molecules15129035
Abstract: It has been accepted that neuroinflammation, oxidative stress and glial activation are involved in the central sensitization underlying neuropathic pain. Vimang is an aqueous extract of Mangifera indica L. traditionally used in Cuba for its analgesic, anti-inflammatory, antioxidant and immunomodulatory properties. Several formulations are available, and also for mangiferin, its major component. Preclinical studies demonstrated that these products prevented tumor necrosis factor α -induced IκB degradation and the binding of nuclear factor κB to DNA, which induces the transcription of genes implicated in the expression of some mediators and enzymes involved in inflammation, pain, oxidative stress and synaptic plasticity. In this paper we propose its potential utility in the neuropathic pain treatment. This hypothesis is supported in the cumulus of preclinical and clinical evidence around the extract and mangiferin, its major component, and speculates about the possible mechanism of action according to recent advances in the physiopathology of neuropathic pain.
Utilidad del Extracto de Mangifera Indica L (VIMANG) en el Síndrome Doloroso Regional Complejo: A propósito de un caso
Garrido-Suárez,B.; Bosch,F.; Garrido-Garrido,G.; Delgado-Hernández,R.; Porro,J. N.; Manero,J. M.;
Revista de la Sociedad Espa?ola del Dolor , 2007,
Abstract: advances in our understanding of complex regional pain syndrome (crps) physiopathology have led to new drugs targeted toward molecular mediators involved in the complex mechanisms of pain. neuroinflammation is thought to have an active role in phenomena underlying spinal cord dorsal horn hyperexcitability and the establishment of central sensitivity. an extract from the bark of selected mangifera indica l species, registered under the vimang? trade mark in cuba, has antioxidant, anti-inflammatory and antihyperanalgesic activity in vivo. in vitro studies have demonstrated that it has an inhibitory effect on several molecules mediating the central sensitization cascade and an ischemic-reperfusion model has proved its cerebral neuroprotective qualities. we present a patient with type ii crps secondary to a brachial plexus lesión following a displaced left humerus fracture that sectioned the radius nerve. the patient presented in our pain clinic four months after the accident with sensorial symptoms, persistent burning pain mechanical allodynia, oedema, vasomotor alterations tending to hyperhaemia and a flexed hand due to loss of the motor function in the fore arm extensors. carpal and shoulder joint movement was severely limited and she scored 5 on the likert pain scale. electrophysiological study revealed mild myelin-axonal alterations in the median nerve and severe alterations in the radial nerve. treatment with vimang (300 mg; 2 tablets/8 hours/4 months) with topical administration of vimang cream 3 times per day combined with sympathetic and somatic nerve blocks in the upper limb and physiotherapy were begun. the patient's clinical and electrophysiological evolution was very favourable. this is the first description of the use of this product in combined crps therapy. our results indicate that further basic and clinical research into the use of vimang? for crps is justified.
Report of cases in patients with acute herpetic neuralgia using a Mangifera indica extract
Beatriz Garrido-Suárez,Gabino Garrido,Rene Delgado,Fe Bosch
Revista Brasileira de Farmacognosia , 2011,
Abstract: It has been accepted that neuroinflammation, oxidative stress and glial activation are involved in the central sensitization underlying neuropathic and inflammatory pain. Vimang is the brand name of an aqueous extract of Mangifera indica L., Anacardiaceae, traditionally used in Cuba for its antioxidant, antiinflammatory, analgesic, and immunomodulatory properties. In the present study, we determined the possible effects of Vimang formulations in acute herpes zoster (n=12) patients, that received a daily dose of 1800 mg of extract (two coated Vimang tablets, 300 mg each, three times daily before meals) associated to low doses of amitriptyline (10-25 mg/d). In addition to the tablets, they utilized compresses containing Vimang dissolution at 2% on skin lesions for thirty days. The average daily pain score using a Likert scale and variations in concomitant drug daily dosage were determined. The analgesic effect was observed from week 1 (p<0.001) with respect to baseline data and none showed post-herpetic neuralgia. Significant reduction of antidepressant medication (p<0.01) and analgesic rescue dosages (p=0.0035) with respect to the initial daily dosage were showed. No adverse events were reported. The results obtained in this report of cases suggest that Vimang supplementation might be beneficial to prevent and treat neuropathic pain.
Report of cases in patients with acute herpetic neuralgia using a Mangifera indica extract
Garrido-Suárez, Beatriz;Garrido, Gabino;Delgado, Rene;Bosch, Fe;Rabí, María del C.;Hernández, Camilo E.;
Revista Brasileira de Farmacognosia , 2011, DOI: 10.1590/S0102-695X2011005000125
Abstract: it has been accepted that neuroinflammation, oxidative stress and glial activation are involved in the central sensitization underlying neuropathic and inflammatory pain. vimang? is the brand name of an aqueous extract of mangifera indica l., anacardiaceae, traditionally used in cuba for its antioxidant, antiinflammatory, analgesic, and immunomodulatory properties. in the present study, we determined the possible effects of vimang formulations in acute herpes zoster (n=12) patients, that received a daily dose of 1800 mg of extract (two coated vimang tablets, 300 mg each, three times daily before meals) associated to low doses of amitriptyline (10-25 mg/d). in addition to the tablets, they utilized compresses containing vimang dissolution at 2% on skin lesions for thirty days. the average daily pain score using a likert scale and variations in concomitant drug daily dosage were determined. the analgesic effect was observed from week 1 (p<0.001) with respect to baseline data and none showed post-herpetic neuralgia. significant reduction of antidepressant medication (p<0.01) and analgesic rescue dosages (p=0.0035) with respect to the initial daily dosage were showed. no adverse events were reported. the results obtained in this report of cases suggest that vimang supplementation might be beneficial to prevent and treat neuropathic pain.
Síndrome doloroso regional complejo tipo 1: Tratamiento mediante bloqueos simpáticos y más... Complex regional pain syndrome type I: Management with sympathetic blockade and other therapies…
B. Garrido,L. Fernández-Suárez,F. Bosch,M. C. Rabí
Revista de la Sociedad Espa?ola del Dolor , 2005,
Abstract: Introducción: El síndrome doloroso regional complejo tipo 1 (SDRC-I) cursa con una fase aguda de inflamación neurogénica regional, que conduce a una fase crónica de desórdenes neuropáticos. La participación del sistema nervioso simpático en su génesis y mantenimiento es significativa, pero no exclusiva. De ahí la importancia de un tratamiento precoz y multifactorial, dirigido a los mecanismos fisiopatológicos. Objetivos: Estudiar el uso de los bloqueos simpáticos, asociados a otros procederes y fármacos en su tratamiento. Material y métodos: Se estudiaron 68 pacientes portadores de SDRC-I que acudieron a la Clínica del Dolor, a los que se realizó bloqueo de la cadena simpática ganglionar cervical y lumbar según la localización de la entidad. Todos los pacientes asociaron el hidromasaje en el hogar. Se administraron fármacos coadyuvantes para el control del dolor neuropático, paroxístico y persistente quemante. En los casos con trastornos de la consolidación ósea, se aplicó laserterapia local y TENS en los que presentaban mayor limitación funcional; así como técnicas de fisiatría. Se aplicó la escala análoga visual (EAV) para evaluar la intensidad de la analgesia y se realizó examen físico para la valoración de los trastornos autonómicos. La función articular se consideró mediante la escala de Enneking y cols. para pacientes amputados, modificada por nosotros. Resultados: El dolor se controló en 33 pacientes y 28 descendieron su EAV a niveles álgicos tolerables, para un 89,70% de efectividad terapéutica. La función articular se recuperó en 30 pacientes y 20 quedaron con limitación leve, estos dos grupos con mejor respuesta correspondieron al 73,52% del total de los pacientes, 11 quedaron con limitación moderada y sólo 7, el 10,29% de ellos con limitación severa. Los trastornos vasomotores remitieron en la totalidad de los que presentaron respuesta favorable. Conclusiones: La intensidad de la analgesia y el control de la sintomatología autonómica fue satisfactoria en la mayoría de los pacientes. La función articular fue recuperada en los mismos, por lo que mejoró su calidad de vida. El método se comportó como útil en el tratamiento de los pacientes con SDRC-I estudiados, asociado a otras terapias. Introduction: Complex Regional Pain Syndrome type 1 (CRPS-I) starts with an acute phase of regional neurogenic inflammation that leads to a chronic phase of neuropathic disorders. The involvement of the sympathetic nervous system in its genesis and maintenance is significant, but not exclusive. Consequently, an early and multi-factorial treatment aimed to physiop
Síndrome doloroso regional complejo tipo 1: Tratamiento mediante bloqueos simpáticos y más...
Garrido,B.; Fernández-Suárez,L.; Bosch,F.; Rabí,M. C.; Hernández-Arteaga,M.;
Revista de la Sociedad Espa?ola del Dolor , 2005,
Abstract: introduction: complex regional pain syndrome type 1 (crps-i) starts with an acute phase of regional neurogenic inflammation that leads to a chronic phase of neuropathic disorders. the involvement of the sympathetic nervous system in its genesis and maintenance is significant, but not exclusive. consequently, an early and multi-factorial treatment aimed to physiopathological mechanisms is important. objectives: to study the use of sympathetic blockade associated to other therapies and drugs for the management of crps-i. material and methods: sixty eight patients with crps-1 attending a pain clinic were studied. all of them underwent blockade of the sympathetic cervical and lumbar chain of nodes, depending on the location of the problem. all patients received also hydromassages at home. co-adjuvant drugs were administered for the management of neuropathic, paroxysmal and burning persistent pain. in patients with bone consolidation disorders, local laser-therapy was applied. in patients with greater functional limitations, tens and physiatry techniques were used. a visual analogue scale was used (vas) to assess the degree of analgesia and a physical examination was conducted to assess autonomic disorders. joint function was assessed using the scale of enneking and cols. for patients with amputation, modified by us. results: pain was controlled in 33 patients and 28 reduced their vas score to tolerable pain levels, with a therapeutic effectiveness of 89,70%. joint function was recovered in 30 patients, with a slight limitation remaining in 20. these two groups that achieved a better response represented 73.52% of all patients. a moderate limitation remained in 11 patients and a severe limitation remained in 7 patients, or 10,29%. vasomotor disorders disappeared in all the patients with a favorable response. conclusions: the degree of analgesia and control of autonomic symptoms were satisfactory in most patients. they recovered the joint function and, hence, improved the
MIARMA: An information preserving method for filling gaps in time series. Application to CoRoT light curves
J. Pascual-Granado,R. Garrido,J. C Suárez
Physics , 2014, DOI: 10.1051/0004-6361/201425056
Abstract: The method here presented intends to minimize the effect of the gaps in the power spectra by gap-filling preserving the original information, that is, in the case of asteroseismology, the stellar oscillation frequency content. We make use of a forward-backward predictor based on autoregressive moving average modelling (ARMA) in the time domain. The method MIARMA is particularly suitable for replacing invalid data such as those present in the light curves of the CoRoT satellite due to the pass through the South Atlantic Anomaly, and eventually for the data gathered by the NASA planet hunter Kepler. We select a sample of stars from the ultra-precise photometry collected by the asteroseismic camera on board the CoRoT satellite: the {\delta} Scuti star HD 174966, showing periodic variations of the same order as the CoRoT observational window, the Be star HD 51193, showing longer time variations, and the solar-like HD 49933, with rapid time variations. We showed that in some cases linear interpolations are less reliable to what was believed. In particular: the power spectrum of HD 174966 is clearly aliased when this interpolation is used for filling the gaps; the light curve of HD 51193 presents a much more aliased spectrum than expected for a low frequency harmonic signal; and finally, although the linear interpolation does not affect noticeably the power spectrum of the CoRoT light curve of the solar-like star HD 49933, the ARMA interpolation showed rapid variations previously unidentified that ARMA interprets as a signal. In any case, the ARMA interpolation method provides a cleaner power spectrum, that is, less contaminated by spurious frequencies. In conclusion, MIARMA appears to be a suitable method for filling gaps in the light curves of pulsating stars observed by CoRoT since the method preserves their frequency content, which is a necessary condition for asteroseismic studies.
Page 1 /188150
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.